- Home
- IART vs JANX Comparison
IART vs JANX Comparison
Compare IART & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IART
- JANX
- Stock Information
- Founded
- IART 1989
- JANX 2017
- Country
- IART United States
- JANX United States
- Employees
- IART N/A
- JANX N/A
- Industry
- IART Medical/Dental Instruments
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IART Health Care
- JANX Health Care
- Exchange
- IART Nasdaq
- JANX Nasdaq
- Market Cap
- IART 1.2B
- JANX 1.4B
- IPO Year
- IART 1995
- JANX 2021
- Fundamental
- Price
- IART $15.06
- JANX $24.05
- Analyst Decision
- IART Hold
- JANX Strong Buy
- Analyst Count
- IART 8
- JANX 10
- Target Price
- IART $18.17
- JANX $79.50
- AVG Volume (30 Days)
- IART 1.3M
- JANX 638.7K
- Earning Date
- IART 11-03-2025
- JANX 11-05-2025
- Dividend Yield
- IART N/A
- JANX N/A
- EPS Growth
- IART N/A
- JANX N/A
- EPS
- IART N/A
- JANX N/A
- Revenue
- IART $1,621,738,000.00
- JANX $439,000.00
- Revenue This Year
- IART $5.74
- JANX N/A
- Revenue Next Year
- IART $4.35
- JANX $130.50
- P/E Ratio
- IART N/A
- JANX N/A
- Revenue Growth
- IART 3.53
- JANX N/A
- 52 Week Low
- IART $11.06
- JANX $21.97
- 52 Week High
- IART $27.13
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IART 55.33
- JANX 49.56
- Support Level
- IART $14.92
- JANX $23.62
- Resistance Level
- IART $15.73
- JANX $25.35
- Average True Range (ATR)
- IART 0.60
- JANX 1.16
- MACD
- IART -0.05
- JANX 0.15
- Stochastic Oscillator
- IART 43.52
- JANX 51.57
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.